Please login to the form below

Not currently logged in

IMI and World Anti-Doping Agency join forces

Will share knowledge and collaborate on areas of mutual interest

Pharmaceutical research and developmentThe Innovative Medicines Initiative (IMI) and the World Anti-Doping Agency have signed a Memorandum of Understanding that will enable them to share information and collaborate on areas of common interest.

Both organisations have a significant scientific and medical focus, leading to considerate overlap in their fields of work. Under the agreement, IMI and WADA will work to identify knowledge gaps that are affecting both parties and then establish collaborations to address these needs.

Irene Norstedt, IMI acting executive director, said: “Many aspects of WADA's comprehensive research programme are of direct relevance to the Innovative Medicines Initiative's goal of advancing medicines development. 

“This Memorandum of Understanding will make it easier for us to share ideas and expertise and learn from one another."

The organisations have already identified a number of areas of interest for future collaborations including ageing, frailty, lung function, blood supply, cognition, the long-term effects of medicines and the biological signatures of drug use.

WADA director general David Howman commented: “It is important for WADA to continue to partner with leading pharmaceutical and healthcare research organisations such as IMI for the benefit of our two communities; encouraging collaboration was the very purpose of the Second International Pharmaceutical Conference in Tokyo earlier this year. 

“This partnership will help IMI minimise the risk of abuse of innovative medicines, and it will help WADA develop new strategies to identify substances that could be subject to misuse and abuse by athletes.”

Article by
Kirstie Pickering

15th April 2015

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...